A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

Ulrik Lassen; Lars Henrik Jensen; Paul Morten Mau-Sørensen; Kristoffer Staal Rohrberg; Zaza Ujmajuridze; Anders Jakobsen

doi:10.3109/0284186X.2010.500300

A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

Ulrik Lassen, Lars Henrik Jensen, Paul Morten Mau-Sørensen, Kristoffer Staal Rohrberg, Zaza Ujmajuridze, Anders Jakobsen

22 Citationer (Scopus)

Abstract

Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists. In this study we aimed to find the maximally tolerated dose (MTD) of a two-week schedule of fixed dose rate (FDR) gemcitabine (G), oxaliplatin (O) and capecitabine (C), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (CC).

Originalsprog	Engelsk
Tidsskrift	Acta oncologica
Vol/bind	50
Udgave nummer	3
Sider (fra-til)	448-54
Antal sider	7
DOI	https://doi.org/10.3109/0284186X.2010.500300
Status	Udgivet - 1 apr. 2011

Adgang til dokumentet

10.3109/0284186X.2010.500300

Citationsformater

@article{6f9ff44ca23946c7995d8162b7aef04a,

title = "A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas",

abstract = "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists. In this study we aimed to find the maximally tolerated dose (MTD) of a two-week schedule of fixed dose rate (FDR) gemcitabine (G), oxaliplatin (O) and capecitabine (C), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (CC).",

author = "Ulrik Lassen and Jensen, {Lars Henrik} and Mau-S{\o}rensen, {Paul Morten} and Rohrberg, {Kristoffer Staal} and Zaza Ujmajuridze and Anders Jakobsen",

year = "2011",

month = apr,

day = "1",

doi = "10.3109/0284186X.2010.500300",

language = "English",

volume = "50",

pages = "448--54",

journal = "Acta oncologica ",

issn = "1651-226X",

publisher = "Medical Journals Sweden AB",

number = "3",

}

TY - JOUR

T1 - A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

AU - Lassen, Ulrik

AU - Jensen, Lars Henrik

AU - Mau-Sørensen, Paul Morten

AU - Rohrberg, Kristoffer Staal

AU - Ujmajuridze, Zaza

AU - Jakobsen, Anders

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists. In this study we aimed to find the maximally tolerated dose (MTD) of a two-week schedule of fixed dose rate (FDR) gemcitabine (G), oxaliplatin (O) and capecitabine (C), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (CC).

AB - Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists. In this study we aimed to find the maximally tolerated dose (MTD) of a two-week schedule of fixed dose rate (FDR) gemcitabine (G), oxaliplatin (O) and capecitabine (C), and evaluate the safety and efficacy of this regimen in patients with advanced cholangiocarcinoma (CC).

U2 - 10.3109/0284186X.2010.500300

DO - 10.3109/0284186X.2010.500300

M3 - Journal article

C2 - 20670085

SN - 1651-226X

VL - 50

SP - 448

EP - 454

JO - Acta oncologica

JF - Acta oncologica

IS - 3

ER -

A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater